{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-023083","form_type":"8-K","ticker":"SANA","cik":"0001770121","company_name":"Sana Biotechnology, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.466195+00:00","generated_at":"2026-06-05T07:09:39.936920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Sana Biotechnology reports Q4 net loss $88.1M; cash $205M; raises $190M in Feb; 40-60 patients in 2024","bullets":["Q4 2023 net loss $88.1M ($0.45/share); full year net loss $283.3M ($1.46/share).","Cash $205.2M at Dec 31, 2023; Feb 2024 offering raised $189.8M gross proceeds to fund pipeline.","Plans to treat 40-60 patients in 2024 across 4 trials in oncology, autoimmune, and type 1 diabetes.","Early SC291 data safe, immune evasion, early efficacy; IND cleared for SC291 in autoimmune and SC262 in B-cell malignancies.","Appointed Doug Williams President R&D, Gary Meininger CMO; expects 2024 operating burn <$200M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-023083","json":"https://secwatch.observer/filing/0000950170-24-023083.json","markdown":"https://secwatch.observer/filing/0000950170-24-023083.md","text":"https://secwatch.observer/filing/0000950170-24-023083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/0000950170-24-023083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/sana-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:09:39.936920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"75f53f8fef9db3a8037bf4abf5755de8df302d53","claim":"Sana Biotechnology, Inc. reported financial results for the quarter and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770121/000095017024023083/0000950170-24-023083-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}